[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$mltxs
Crypto markets are experiencing volatility. Investors are reacting to the latest project developments.
About $mltxs
A cryptocurrency project.
Engagements: X #
Engagements 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: XX
1 Week: XX -XXX%
1-Year High: XX on 2025-04-27
1-Year Low: X on 2025-06-11
| Social Network | X |
|---|---|
| Engagements | X |
Mentions: X #
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
1-Year High: X on 2025-10-15
1-Year Low: X on 2025-04-27
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $mltxs in the last XX hours which is up XXX% from X in the previous XX hours
Daily Average: X
1-Year High: X on 2025-10-15
1-Year Low: X on 2025-04-27
Top assets mentioned In the posts about $mltxs in the last XX hours
MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Core Scientific, Inc. Common Stock (CORZ) United Community Banks, Inc. (UCB) Sanofi (SNY) Synthetify (SNY)
Top topics mentioned In the posts about $mltxs in the last XX hours
$mltx, core scientific, stocks bitcoin treasuries, stocks bitcoin miners, $ucb, longterm, dough, $snys, sanofi, stocks healthcare, $sny
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$UCB (Buy)-Bimzelx's Strong Launch Trajectory Should Continue LT In Massive HS Markethave high conviction in Bimzelx's long-term potential which is solidified by $MLTX's sonelokimab HS results. Bimzelx's impressive real-world efficacy has exceeded all expectations and UCB will be incumbent in a large&growing HS market. reiterate our 6B+ Bimzelx peak sales estimate driven by 3B+ opportunity in HS alone. UCB is a clear Buy for the durable earnings growth"
X Link @semodough 2025-09-29T15:14Z 41.4K followers, 3189 engagements
"$mltx from Grok Feuerstein s misses tend to come on stock price predictions or M&A speculation (20-30% wrong) not core scientific critiques like $MLTXs VELA setup. For $MLTX specifically his bear case hinges on sonelokimab underperforming vs. Bimzelx due to trial design and benchmark issuesclassic Feuerstein territory where hes rarely off (10% miss rate). But if VELAs Phase X data exceeds expectations (e.g. HiSCR75 significantly above Bimzelxs 33-36%) he could be in that slim XX% wrong bucket. Keep an eye on his X posts (@adamfeuerstein) for real-time updates post-readout"
X Link @Biotekster 2025-09-28T15:40Z XXX followers, XXX engagements
"$SNY's anti-TNFalpha-OX40 dual-targeting nanobody rocks in hidradenitis supp with unprecedented p2 HiSCR75 delta of XX% (cf $MLTX's dual targeting-nanobody 29%)"
X Link @RNAiAnalyst 2025-09-17T07:43Z 20.5K followers, 11.2K engagements